Predict your next investment

HEALTHCARE | Biotechnology
cardioxyl.com

See what CB Insights has to offer

Executives

8

Board of Directors

4

Cardioxyl Pharmaceuticals Board of Directors

4 Board of directors

Cardioxyl Pharmaceuticals has 4 board of directors, including James Barrett.

Name

Firm

Work History

Other Seats

James Barrett

Jim joined NEA in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships include Amicus Therapeutics, Cardioxyl Pharmaceuticals, Clovis Oncology, GlycoMimetics, Inc., PhaseBio Pharmaceuticals, Predictive Biosciences, Psyadon Pharmaceuticals, Roka Bioscience, Senseonics, Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc. Jim formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), Iomai Corporation (acquired by Intercell AG), MedImmune, Inc. (acquired by AstraZeneca), Pharmion (acquired by Celgene), Inhibitex, Inc. (NASDAQ: INHX, acquired by Bristol-Myers Squibb), and Peptimmune, Inc. Prior to NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Jim worked in various divisions of SmithKline. Jim received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.

Cardioxyl Pharmaceuticals

Jeff Clark

Jeff Clark co-founded The Aurora Funds with ScottAlbert in 1994. He works primarily with Aurora's lifesciences portfolio. He pulls from his strategicplanning and operational experience to help thesecompanies create or refine business plans, build solidmanagement teams, develop strategic partnerships andsecure key customers.Jeff currently serves on the boards of several ofAurora's life science portfolio companies, includingAldagen, Argos Therapeutics, Hyperbranch MedicalTechnology, Metabolon, Regado Biosciences and XsiraPharmaceuticals assisting in the strategic directionof each.Prior to forming Aurora, Jeff spent thirteen yearsworking in development and external affairs for DukeUniversity (including Duke Comprehensive CancerCenter, Duke Medical Center and the School ofEngineering). Through Aurora, he hoped to close thegap between local universities and the venture capitalcommunity to facilitate the growth of life sciencecompanies.Jeff maintains strong ties to the RTP community,serving as past Chairman of the Board of NorthCarolina's Council for Entrepreneurial Development,the Board of Overseers of the Duke ComprehensiveCancer Center and the Board of Directors for TROSA andthe Choral Society of Durham. Jeff is also FoundingChair of NC EntrePAC and associated entities.Jeff holds a Bachelor of Science in MechanicalEngineering from Duke University and a MBA from theFuqua School of Business at Duke University.

Cardioxyl Pharmaceuticals

Peter Thompson

Peter represents Orbimed on the Board of Directors. Peter Thompson, M.D., is a Partner on the private equity team of Orbimed and has more than 25 years of industry experience. He held executive positions at Becton-Dickinson and Chiron; cofounded and was CEO of Trubion Pharmaceuticals; cofounded Corvus Pharmaceuticals, Cleave Biosciences, and Silverback Therapeutics; and serves as a Director on several company boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

Cardioxyl Pharmaceuticals

Robert Garland

Rob has over 27 years of experience focused on mineral and energy resources development in the Rocky Mountain region with emphasis on environmental site assessment, remediation, regulatory permitting & compliance, and water resource development & management. After consulting as well as working for energy development and environmental consulting firms from 1982 to 1998 he formed InterTech Environmental & Engineering, LLC in 1999 and was the managing partner and Senior Hydrogeologist. He sold InterTech to Apex Companies in 2015 and currently works for them as a client Program Manager. He is a registered Professional Geologist in Wyoming and has a B.S. in Petroleum Geology ‘82 and an M.S. in Hydrogeology and Water Resources ’96 from the University of Wyoming.

Cardioxyl Pharmaceuticals

Name

James Barrett

Jeff Clark

Peter Thompson

Robert Garland

Firm

Work History

Jim joined NEA in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships include Amicus Therapeutics, Cardioxyl Pharmaceuticals, Clovis Oncology, GlycoMimetics, Inc., PhaseBio Pharmaceuticals, Predictive Biosciences, Psyadon Pharmaceuticals, Roka Bioscience, Senseonics, Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc. Jim formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), Iomai Corporation (acquired by Intercell AG), MedImmune, Inc. (acquired by AstraZeneca), Pharmion (acquired by Celgene), Inhibitex, Inc. (NASDAQ: INHX, acquired by Bristol-Myers Squibb), and Peptimmune, Inc. Prior to NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Jim worked in various divisions of SmithKline. Jim received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.

Jeff Clark co-founded The Aurora Funds with ScottAlbert in 1994. He works primarily with Aurora's lifesciences portfolio. He pulls from his strategicplanning and operational experience to help thesecompanies create or refine business plans, build solidmanagement teams, develop strategic partnerships andsecure key customers.Jeff currently serves on the boards of several ofAurora's life science portfolio companies, includingAldagen, Argos Therapeutics, Hyperbranch MedicalTechnology, Metabolon, Regado Biosciences and XsiraPharmaceuticals assisting in the strategic directionof each.Prior to forming Aurora, Jeff spent thirteen yearsworking in development and external affairs for DukeUniversity (including Duke Comprehensive CancerCenter, Duke Medical Center and the School ofEngineering). Through Aurora, he hoped to close thegap between local universities and the venture capitalcommunity to facilitate the growth of life sciencecompanies.Jeff maintains strong ties to the RTP community,serving as past Chairman of the Board of NorthCarolina's Council for Entrepreneurial Development,the Board of Overseers of the Duke ComprehensiveCancer Center and the Board of Directors for TROSA andthe Choral Society of Durham. Jeff is also FoundingChair of NC EntrePAC and associated entities.Jeff holds a Bachelor of Science in MechanicalEngineering from Duke University and a MBA from theFuqua School of Business at Duke University.

Peter represents Orbimed on the Board of Directors. Peter Thompson, M.D., is a Partner on the private equity team of Orbimed and has more than 25 years of industry experience. He held executive positions at Becton-Dickinson and Chiron; cofounded and was CEO of Trubion Pharmaceuticals; cofounded Corvus Pharmaceuticals, Cleave Biosciences, and Silverback Therapeutics; and serves as a Director on several company boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

Rob has over 27 years of experience focused on mineral and energy resources development in the Rocky Mountain region with emphasis on environmental site assessment, remediation, regulatory permitting & compliance, and water resource development & management. After consulting as well as working for energy development and environmental consulting firms from 1982 to 1998 he formed InterTech Environmental & Engineering, LLC in 1999 and was the managing partner and Senior Hydrogeologist. He sold InterTech to Apex Companies in 2015 and currently works for them as a client Program Manager. He is a registered Professional Geologist in Wyoming and has a B.S. in Petroleum Geology ‘82 and an M.S. in Hydrogeology and Water Resources ’96 from the University of Wyoming.

Other Seats

Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals Management Team

8 Team Members

Cardioxyl Pharmaceuticals has 8 executives. Cardioxyl Pharmaceuticals's founder is Vincent J Kalish. Cardioxyl Pharmaceuticals's current Chief Security Officer is John Reardon.

Name

Work History

Title

Status

John Reardon

Chief Security Officer

Current

Doug Cowart

Executive Vice President

Current

Richard Schwarz

Senior Director

Current

Vincent J Kalish

Founder

Former

Chris Kroeger

Chief Executive Officer

Former

Name

John Reardon

Doug Cowart

Richard Schwarz

Vincent J Kalish

Chris Kroeger

Work History

Title

Chief Security Officer

Executive Vice President

Senior Director

Founder

Chief Executive Officer

Status

Current

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.